<DOC>
	<DOCNO>NCT02065479</DOCNO>
	<brief_summary>Numerous study show pharmacodynamics ( PD ) response profile vary among clopidogrel treat patient individual reduce response increase risk recurrent ischemic event . There multiple factor contribute clopidogrel response variability , include genetic variation cytochrome P450 ( CYP ) 2C19 enzyme . In particular , loss-of-function ( LOF ) alleles CYP2C19 enzyme reduce transformation clopidogrel pro-drug active metabolite . Thus , patient carry LOF allele low level clopidogrel 's active metabolite well diminished platelet inhibition , translates increase rate adverse cardiovascular event , particularly set percutaneous coronary intervention ( PCI ) . Prasugrel ticagrelor novel generation P2Y12 receptor inhibitor characterize great PD potency reduce ischemic event rate compare clopidogrel , affect CYP2C19 LOF polymorphism . However , date limit head-to-head PD comparison two new P2Y12 receptor blocker , study assess agent behave among CYP2C19 LOF carrier . The aim present study compare PD effect prasugrel versus ticagrelor patient undergo PCI CYP2C19 LOF alleles use novel point-of-care genetic test Spartan RX-CYP2C19 permit accurate rapid identification CYP2C19 genetic status .</brief_summary>
	<brief_title>A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor Patients Undergoing PCI With CYP2C19 Loss-of-function :</brief_title>
	<detailed_description>Clopidogrel broadly utilize platelet P2Y12 receptor inhibitor . However , numerous study show pharmacodynamics ( PD ) response profile vary among clopidogrel treat patient individual reduce response increase risk recurrent ischemic event . There multiple factor contribute clopidogrel response variability . Among , genetic variation cytochrome P450 ( CYP ) 2C19 enzyme , key contributor clopidogrel metabolism , involve . In particular , loss-of-function ( LOF ) alleles CYP2C19 enzyme reduce transformation clopidogrel pro-drug active metabolite . Thus , patient carry LOF allele low level clopidogrel 's active metabolite well diminished platelet inhibition , translates increase rate adverse cardiovascular event , particularly set percutaneous coronary intervention ( PCI ) . Because finding , drug regulating authority provide boxed warning product label clopidogrel potential reduce efficacy clopidogrel among CYP2C19 LOF carrier suggest consider alternative antiplatelet therapy individual . Prasugrel ticagrelor novel generation P2Y12 receptor inhibitor characterize great PD potency reduce ischemic event rate compare clopidogrel , affect CYP2C19 LOF polymorphism . However , date limit head-to-head PD comparison two new P2Y12 receptor blocker , study assess agent behave among CYP2C19 LOF carrier . Tailoring antiplatelet therapy accord result genetic test limited real world clinical practice readily accessible result individual 's genetic makeup . The aim present study compare PD effect prasugrel versus ticagrelor patient undergo PCI CYP2C19 LOF alleles use novel point-of-care genetic test Spartan RX-CYP2C19 permit accurate rapid identification CYP2C19 genetic status .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients schedule left heart catheterization undergo PCI 2 . Age 1875 year 3 . On aspirin ( 81mg ) aspirin ( 81mg ) clopidogrel ( 75mg/day ) 4 . Presence least one 2C19 LOF allele Exclusion criterion : 1 . Known allergy aspirin , prasugrel , ticagrelor , clopidogrel 2 . Age &gt; 75 year 3 . Weight &lt; 60kg 4 . Considered high risk bleed 5 . History ischemic hemorrhagic stroke transient ischemic attack 6 . Known severe hepatic dysfunction 7 . On treatment oral anticoagulant therapy ( Vitamin K antagonist , dabigatran , apixaban , rivaroxaban ) 8 . Use glycoprotein IIb/IIIa inhibitor ( abciximab , eptifibatide , tirofiban ) 9 . Blood dyscrasia bleed diathesis 10 . Platelet count &lt; 80x106/mL 11 . Hemoglobin &lt; 10 g/dL . 12 . Active bleed hemodynamic instability 13 . Creatinine Clearance &lt; 30 mL/minute 14 . Patients sick sinus syndrome ( SSS ) high degree AV block without pacemaker protection . 15 . Current treatment drug interfere CYP3A4 metabolism ( avoid interaction Ticagrelor ) : Ketoconazole , itraconazole , voriconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , telithromizycin . 16 . Pregnant females* *Women childbearing age must use reliable birth control ( i.e . oral contraceptive ) participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Genetic Polymorphism</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>